HER2/NEU NEGATIVE

This study tests whether giving two immunotherapy drugs (decitabine and pembrolizumab) before standard chemotherapy can boost the body's immune attack on HER2-negative breast cancer. About 46 adults with locally advanced disease will receive this short course, then proceed to usu…

This study tests whether platinum-based chemotherapy (cisplatin or carboplatin) works better than capecitabine in people with a certain type of triple-negative breast cancer that still remains after initial chemotherapy and surgery. About 415 participants with stage II or III bre…

This study tested a chemotherapy combination (carboplatin and nab-paclitaxel) given before surgery to people with a fast-growing type of breast cancer called triple negative. The goal was to shrink tumors enough so that no cancer remains at the time of surgery. The study included…

This early-phase trial studies two drug combinations (olaparib plus vistusertib or olaparib plus capivasertib) in people with recurrent endometrial, triple-negative breast, ovarian, or related cancers. The main goal is to find the safest dose and understand side effects. About 15…

This early-stage study tests a new cancer vaccine (p53MVA) combined with the immunotherapy drug pembrolizumab in people with advanced solid tumors that have not responded to other treatments. The vaccine helps the immune system recognize and attack cancer cells, while pembrolizum…

This study tested whether adding the drug entinostat to standard hormone therapy (exemestane) helps people with advanced hormone receptor-positive breast cancer live longer without their cancer growing. About 600 adults with breast cancer that had spread or come back took part. T…

This study tested whether adding trastuzumab to standard chemotherapy before surgery helps shrink breast tumors more effectively. About 92 women with early-stage breast cancer (some HER2-positive, some HER2-negative) took part. The goal was to see if the combination reduces the a…

This study tests whether giving radiation therapy before surgery can shrink hormone receptor-positive, HER2-negative breast tumors. About 25 adults with this type of breast cancer will receive radiation to the tumor area before their surgery. The goal is to see if this approach r…

This study tests a drug called pembrolizumab in people with advanced inflammatory breast cancer or triple-negative breast cancer that has spread. Participants had already responded to or stabilized with chemotherapy. The drug helps the immune system attack cancer cells, and the g…

This study looks at whether the drug ixabepilone can help people with HER2-negative breast cancer who still have cancer after standard chemotherapy. About 116 participants will either receive ixabepilone or be observed. The goal is to see if the drug can reduce the risk of cancer…

This study compares two different chemotherapy combinations given before surgery for a fast-growing, hard-to-treat type of breast cancer called triple-negative inflammatory breast cancer. Researchers want to see if adding a targeted drug called panitumumab to standard chemotherap…

This study is testing whether a special PET scan called FES PET/CT can predict how well hormone therapy will work for people with newly diagnosed breast cancer that has spread. The scan uses a radioactive form of estrogen to light up cancer cells that respond to hormones. About 9…

This study looks at whether watching an online genetics video, with or without phone counseling, can reduce the stress women feel about their cancer risk. It involves 5,200 women aged 30 or older who have had triple-negative breast cancer and still have at least one ovary. Resear…

This study looks at whether advanced breast imaging scans can predict how well chemotherapy is working in people with triple negative breast cancer. About 96 participants will get special MRI and molecular breast imaging scans before, during, and after chemo. The goal is to see i…